Oct 7, 2024, 16:42
Neoadjuvant therapy for resectable pancreatic cancer suggested by Alan Burguete-Torres
Alan Burguete-Torres, Gastrointestinal Cancer Specialist at Centro Médico Zambrano Hellion, shared a post on X:
“New study on neoadjuvant therapy for resectable pancreatic cancer shows no improvement in overall survival rates. This highlights the need for further research to optimize treatment strategies.”
Authors: Daniel Aliseda, Pablo Martí-Cruchaga, Gabriel Zozaya, Nuria Blanco, Mariano Ponz, Ana Chopitea, Javier Rodríguez, Eduardo Castañón, Fernando Pardo and Fernando Rotellar.
Source: Alan Burguete-Torres/X
Alan Burguete-Torres
Ana Chopitea
cancer
cancer awareness
cancer care
Cancer research
Daniel Aliseda
Eduardo Castañón
Fernando Pardo
Fernando Rotellar
fight against cancer
Gabriel Zozaya
Global fight against cancer
Javier Rodríguez
Mariano Ponz
Nuria Blanco
OncoDaily
Oncology
Pablo Martí-Cruchaga
Pancreatic Cancer
resectable pancreatic cancer
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 00:19
Nov 14, 2024, 00:02
Nov 13, 2024, 23:57
Nov 13, 2024, 23:54
Nov 13, 2024, 23:48
Nov 13, 2024, 23:46